Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pfenex Awarded a Subcontract by Leidos

Published: Thursday, October 31, 2013
Last Updated: Thursday, October 31, 2013
Bookmark and Share
Funding will be provided by Leidos through its Malaria Vaccine Production and Support Services Contract with NIAID, part of the National Institutes of Health.

Pfenex Inc. has announced that Leidos Holdings, Inc. (formerly SAIC) has awarded Pfenex a subcontract to develop a robust, scalable, cGMP-ready production process for large-scale production of the blood-stage malaria antigen Plasmodium falciparum reticulocyte-binding homolog 5 (Rh5).

This contract is a result of successful pre-clinical studies performed by Leidos collaborators to evaluate the Rh5 antigen that was produced using the Pfēnex Expression Technology™ platform.

The subcontract is funded with federal funds from Leidos’ prime Malaria Vaccine Production and Support Services (MVPSS) contract (N01.AI.05421) from the National Institute of Allergy and Infectious Diseases (NIAID).

This is the second subcontract awarded to Pfenex for the development of critical, hard-to-express malaria antigens. Leidos had previously awarded Pfenex a subcontract to develop a scalable, cGMP-ready production process for large-scale production of full length Circumsporozoite protein (CSP) from P. falciparum.

“We are pleased to be awarded this contract as we expand our effort to find an effective therapy for malaria," stated Bertrand C. Liang, Pfenex’s Chief Executive Officer. “Pfēnex Expression Technology™ has once again demonstrated its ability to efficiently produce a high–value, complex protein enabling the potential of a multivalent malaria vaccine.”

Pfenex will immediately commence process development activities while continuing to provide materials to Leidos and NIAID for ongoing preclinical studies.

“Working with Pfenex and NIAID on this program is an important step in the development of an effective malaria vaccine,” said James Pannucci, Ph.D., vice president of the Leidos Health Life Sciences team. “We hope our work will lead to new discoveries and have a profound effect on the world’s health.”

The Leidos Life Science team operates a virtual drug development enterprise that bridges the gap between federal agencies and commercial clients, along with a modest portfolio of vaccine and therapeutic candidates.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pfenex to Regain Full Rights to PF582
Pfenex has announced that the company will regain the full rights to PF582, a biosimilar candidate to Lucentis®, following Hospira's strategic review of the current therapeutic focus of its biosimilar pipeline.
Tuesday, August 09, 2016
Pfenex and PATH Partner on Vaccines
Initiation of a multi-product research program with PATH.
Saturday, October 11, 2014
Pfenex Awards a Contract to Paragon Bioservices
Contract for cGMP manufacturing of recombinant protective antigen, for phase 1 clinical trial of Company’s anthrax vaccine.
Thursday, November 07, 2013
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Developing a Vaccine for Sexually Transmitted and Insect-Borne Zika Infections
Prokarium announce the beginning of a programme to develop an oral vaccine against Zika infection.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!